Affordable Access

Publisher Website

Peanut Oral Immunotherapy: Is It Ready for Clinical Practice?

Authors
Journal
The Journal of Allergy and Clinical Immunology In Practice
2213-2198
Publisher
Elsevier
Volume
1
Issue
1
Identifiers
DOI: 10.1016/j.jaip.2012.10.009
Keywords
  • Clinical Commentary
Disciplines
  • Design
  • Medicine

Abstract

The prevalence of peanut allergy in the United States and other Westernized countries has tripled in the past 15 years, now affecting more than 1% of the population. Strict peanut avoidance is the current standard of care. In the past decade, a number of small, largely uncontrolled clinical trials have suggested that oral immunotherapy (OIT) can effectively desensitize most children with peanut allergy. Some in the allergy community now feel that OIT is ready for clinical practice. In this review, the evidence base in the medical literature is examined. Although peanut OIT shows promise, the evidence currently available on its effectiveness, risk benefit, and potential long-term consequences is insufficient to support its use in clinical practice. Appropriately designed, prospective clinical trials are urgently needed to determine whether OIT is a safe, effective form of therapy for food allergy.

There are no comments yet on this publication. Be the first to share your thoughts.

Statistics

Seen <100 times
0 Comments

More articles like this

Oral immunotherapy for peanut allergy in clinical...

on Allergy and Asthma Proceedings 2013

Peanut oral immunotherapy is not ready for clinica...

on Journal of Allergy and Clinica... July 2010

Oral immunotherapy for the treatment of peanut all...

on The journal of allergy and cli... 2014

Oral and sublingual peanut immunotherapy is not re...

on Allergy and Asthma Proceedings 2013
More articles like this..